ERBB2 and breast cancer: For instance, knocking down HCAR1 in a HER2-enriched BC cell line, HCC1954 (ER-, PR-, HER2 +), and triple-negative BC cell line, HCC38 (ER-, PR-, HER2-), resulted in a significant decrease of cell viability within 48 h of transfection.